MAP
HZNP

Moody Aldrich Partners’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Moody Aldrich Partners’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-2,417
Closed -$280K – 230
2023
Q3 		$280K Buy
+2,417
New +$260K 0.05% 165
2019
Q3 		– Sell
-65,034
Closed -$1.56M – 149
2019
Q2 		$1.56M Buy
+65,034
New +$1.65M 0.4% 82

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Moody Aldrich Partners's HZNP Position: Q4 2023 in Review

Moody Aldrich Partners sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 2,417 shares — an estimated $280K sold.

Moody Aldrich Partners first reported a position in HZNP in Q2 2019 and held it in 2 quarters. The position peaked at $1.56M in Q2 2019. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Moody Aldrich Partners reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Moody Aldrich Partners sold 2,417 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $280K.
  • Moody Aldrich Partners first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2019 and held it in 2 quarters.
  • Moody Aldrich Partners's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $1.56M in Q2 2019.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Moody Aldrich Partners's 13F filing for Q4 2023, filed 26 Jan 2024.